• Publications
  • Influence
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα
Vince et al. 2008. J. Cell Biol. doi:10.1083/jcb.200801010 [OpenUrl][1][Abstract/FREE Full Text][2] [1]:Expand
  • 113
  • 13
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
WIN 51711 and WIN 52084 are structurally related, antiviral compounds that inhibit the replication of rhino (common cold) viruses and related picornaviruses. They prevent the pH-mediated uncoating ofExpand
  • 397
  • 9
Crystal structure of human rhinovirus serotype 1A (HRV1A).
The structure of human rhinovirus 1A (HRV1A) has been determined to 3.2 A resolution using phase refinement and extension by symmetry averaging starting with phases at 5 A resolution calculated fromExpand
  • 181
  • 9
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
Spontaneous mutants of human rhinovirus 14 resistant to WIN 52084, an antiviral compound that inhibits attachment to cells, were isolated by selecting plaques that developed when wild-type virus wasExpand
  • 105
  • 6
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
The acquisition of apoptosis resistance is a fundamental event in cancer development. Among the mechanisms used by cancer cells to evade apoptosis is the dysregulation of inhibitor of apoptosis (IAP)Expand
  • 109
  • 6
  • Open Access
The structure of human rhinovirus 16.
BACKGROUND Rhinoviruses and the homologous polioviruses have hydrophobic pockets below their receptor-binding sites, which often contain unidentified electron density ('pocket factors'). CertainExpand
  • 141
  • 4
Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1Expand
  • 100
  • 4
Enterovirus meningitis in adults.
  • 72
  • 4
Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.
WIN 51711, a potent new antipicornavirus drug, has been shown to inhibit an early event in the replication cycle of human poliovirus type 2 and human rhinovirus type 2. WIN 51711 was not virucidalExpand
  • 148
  • 3
  • Open Access
Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.
The human rhinoviruses are the leading cause of the ubiquitous, mild, and self-limiting infections generally referred to as the common cold. Considerable research effort has been expended in theExpand
  • 93
  • 3